WO2021145401A1 - Dérivés spirohétérocycliques utilisés comme antagonistes de crhr2 - Google Patents

Dérivés spirohétérocycliques utilisés comme antagonistes de crhr2 Download PDF

Info

Publication number
WO2021145401A1
WO2021145401A1 PCT/JP2021/001150 JP2021001150W WO2021145401A1 WO 2021145401 A1 WO2021145401 A1 WO 2021145401A1 JP 2021001150 W JP2021001150 W JP 2021001150W WO 2021145401 A1 WO2021145401 A1 WO 2021145401A1
Authority
WO
WIPO (PCT)
Prior art keywords
methyl
cyclohexyl
chloro
azetidine
difluoromethyl
Prior art date
Application number
PCT/JP2021/001150
Other languages
English (en)
Inventor
Masashi Ohmi
Tatsuya Yamagishi
Ryuichi Yamaguchi
Yutaka Fukumoto
Kazuo Ando
Original Assignee
Raqualia Pharma Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Raqualia Pharma Inc. filed Critical Raqualia Pharma Inc.
Publication of WO2021145401A1 publication Critical patent/WO2021145401A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

La présente invention concerne des dérivés spirohétérocycliques qui ont des activités antagonistes contre CRHR2, et qui sont utiles dans le traitement ou la prévention de troubles et de maladies dans lesquels CRHR2 est impliqué. L'invention concerne également des compositions pharmaceutiques comprenant ces composés et l'utilisation de ces composés et compositions dans la prévention ou le traitement de telles maladies dans lesquelles CRHR2 est impliqué.
PCT/JP2021/001150 2020-01-15 2021-01-15 Dérivés spirohétérocycliques utilisés comme antagonistes de crhr2 WO2021145401A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202062961286P 2020-01-15 2020-01-15
US62/961,286 2020-01-15

Publications (1)

Publication Number Publication Date
WO2021145401A1 true WO2021145401A1 (fr) 2021-07-22

Family

ID=76864443

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2021/001150 WO2021145401A1 (fr) 2020-01-15 2021-01-15 Dérivés spirohétérocycliques utilisés comme antagonistes de crhr2

Country Status (2)

Country Link
TW (1) TW202140480A (fr)
WO (1) WO2021145401A1 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11976067B2 (en) 2022-01-18 2024-05-07 Maze Therapeutics, Inc. APOL1 inhibitors and methods of use

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004089307A2 (fr) * 2003-04-04 2004-10-21 Merck & Co. Inc. Derives de spiropiperidine acyles utilises comme agonistes vis-a-vis du recepteur de melanocortine-4
WO2005092858A2 (fr) * 2004-03-29 2005-10-06 Pfizer Japan Inc. Composes alpha-aryle ou heteroaryle methyle beta piperidino propanamide en tant qu'antagoniste du recepteur orl1
WO2011092293A2 (fr) * 2010-02-01 2011-08-04 Novartis Ag Dérivés de cyclohexylamide utilisés en tant qu'antagonistes du récepteur du crf
WO2011095450A1 (fr) * 2010-02-02 2011-08-11 Novartis Ag Dérivés de cyclohexylamide à titre d'antagonistes du récepteur crf
WO2019198692A1 (fr) * 2018-04-09 2019-10-17 Raqualia Pharma Inc. Dérivés d'urée cyclique fusionnés utilisés comme antagonistes de crhr2

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004089307A2 (fr) * 2003-04-04 2004-10-21 Merck & Co. Inc. Derives de spiropiperidine acyles utilises comme agonistes vis-a-vis du recepteur de melanocortine-4
WO2005092858A2 (fr) * 2004-03-29 2005-10-06 Pfizer Japan Inc. Composes alpha-aryle ou heteroaryle methyle beta piperidino propanamide en tant qu'antagoniste du recepteur orl1
WO2011092293A2 (fr) * 2010-02-01 2011-08-04 Novartis Ag Dérivés de cyclohexylamide utilisés en tant qu'antagonistes du récepteur du crf
WO2011095450A1 (fr) * 2010-02-02 2011-08-11 Novartis Ag Dérivés de cyclohexylamide à titre d'antagonistes du récepteur crf
WO2019198692A1 (fr) * 2018-04-09 2019-10-17 Raqualia Pharma Inc. Dérivés d'urée cyclique fusionnés utilisés comme antagonistes de crhr2

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11976067B2 (en) 2022-01-18 2024-05-07 Maze Therapeutics, Inc. APOL1 inhibitors and methods of use

Also Published As

Publication number Publication date
TW202140480A (zh) 2021-11-01

Similar Documents

Publication Publication Date Title
US9051296B2 (en) Aryl carboxamide derivatives as TTX-S blockers
KR102425400B1 (ko) Trpm8 길항제로 사용되는 아자스피로 유도체
US9556197B2 (en) Furo- and thieno-pyridine carboxamide compounds useful as pim kinase inhibitors
KR20190076976A (ko) Ret 키나제 억제제로서의 치환된 피라졸로[1,5-a]피리딘 화합물
US11802120B2 (en) Fused cyclic urea derivatives as CRHR2 antagonist
KR102067235B1 (ko) Ttx-s 차단제로서 아미드 유도체
ES2780699T3 (es) Amidas de piperidina fusionadas útiles como moduladores de canales iónicos
JP7055528B1 (ja) プロテアーゼ阻害剤としてのケトアミド誘導体
WO2012020567A1 (fr) Dérivés d'acylpipérazine à titre de bloqueurs de ttx-s
TW201336845A (zh) 用於治療退化及發炎疾病之新穎化合物
CA3120268A1 (fr) Derives heterocylciques utilises en tant que bloqueurs nav1.7 et nav1.8
WO2021145401A1 (fr) Dérivés spirohétérocycliques utilisés comme antagonistes de crhr2
WO2022071484A1 (fr) Dérivés de 3-hydroxyoxindole utiles en tant qu'antagonistes du crhr2
RU2778641C2 (ru) Производные конденсированной циклической мочевины в антагонист crhr2
US20230373925A1 (en) Heteroaryl compounds for the treatment of pain

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 21741318

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 21741318

Country of ref document: EP

Kind code of ref document: A1